德展健康：2025年前三季度净利润约-6103万元

Group 1 - The core viewpoint of the news is that 德展健康 (Dezhan Health) reported a significant decline in revenue and incurred a net loss in its third-quarter performance for 2025 [1] - The company's revenue for the first three quarters of 2025 was approximately 278 million yuan, representing a year-on-year decrease of 21.71% [1] - The net profit attributable to shareholders was a loss of approximately 61.03 million yuan, with a basic earnings per share loss of 0.0288 yuan [1] Group 2 - As of the report, 德展健康 has a market capitalization of 8.7 billion yuan [2] - The news highlights the broader context of the biopharmaceutical market, noting that China’s innovative drugs have generated 80 billion US dollars in overseas licensing this year [2] - There is a contrast drawn between the hot secondary market for biopharmaceuticals and the cooling fundraising environment in the primary market [2]